Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform
"This latest patent further expands the global intellectual property position for
About
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of cancer patients, our ability to develop business in major global markets such as
Investor Contact: |
Media Contact: |
LHA |
Trevelino/Keller |
Jody Cain |
Colleen Murphy |
310-691-7100 |
404-214-0722, Ext. 109 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-obtains-japanese-patent-for-its-target-selector-oncogene-mutation-enrichment-and-detection-platform-300733445.html
SOURCE